Hyaltop (sodium hyaluronate) / Shin Poong Pharma - LARVOL DELTA

A Single-center, Exploratory Clinical Study of the Efficacy and Safety of Hyaltopa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent/Sequential Chemoradiotherapy (ChiCTR) - P=N/A | N=30 | Completed | Sponsor: Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University

New trial • Hematological Disorders • Oncology • Thrombocytopenia

Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=297 | Active, not recruiting | Sponsor: Shin Poong Pharmaceutical Co. Ltd.

New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology

Shinpoong OKed for phase 3 study of osteoarthritis drug (Korea Biomedical Review) - "Shinpoong Pharmaceutical said the Ministry of Food and Drug Safety (MFDS) on Thursday approved its phase 3 trial clinical plan for SP5M002 (ingredient: sodium hyaluronate), an investigational knee osteoarthritis drug. The study, which will be randomized, double-blind, and active-controlled, will evaluate the efficacy and safety of intra-articular administration of SP5M002 in patients with knee osteoarthritis. The drug candidate will be tested on 292 adults with mild to moderate knee osteoarthritis. Patients enrolled in the clinical trial will receive either a single or repeat intra-articular injection of SP5M002 or active control to evaluate post-dose efficacy and safety. The study will evaluate the treatment's effectiveness by monitoring changes in pain, swelling, and range of motion for a period of 24 weeks..."

New P3 trial • CNS Disorders • Osteoarthritis • Pain